Topic: Imexpharm

Imexpharm earns CSA 2025 recognition for advancing sustainable pharma practices through ESG, innovation, and community-focused initiatives.

The deal valued at over VND5.73 trillion ($220.6 million).

Imexpharm aims for VND2,981 billion in total revenue and VND493.5 billion in profit before tax in 2025, focusing on high-tech products, R&D, and market expansion.

Imexpharm kicked off Q1 2025 with impressive results, reporting net revenue of VND594 billion and profit before tax of VND95 billion in Q1 2025, up 21 per cent and 23 per cent year-on-year (YoY), respectively.

Imexpharm supports Da Lat’s tree-planting initiative, reinforcing its commitment to environmental sustainability and community well-being.

The long-term growth prospects of Vietnamese pharmaceutical companies are on the rise as they establish their position in the high-tech product segment, competing in both domestic and international markets.

Award comes in recognition of its commitment to employee growth.

With a team of leading talent in the pharmaceutical industry, Imexpharm is driving significant growth by boosting R&D as a strategy to develop high-tech pharmaceuticals.

The Imexpharm Pharmaceutical Joint Stock Company is committed to significantly investing in sustainable development as a strategic path to drive its future expansion into the global market.

The Imexpharm Pharmaceutical Joint Stock Company has been listed in the Top 50 Corporate Sustainability Awards 2023 held by the Nhip Cau Dau Tu - The BusinessReview magazine.